Currently, SITC has more than 4,650 members who represent over 35 medical specialties in 63 countries around the world.

SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. 

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.

SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

Mission Statement

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation, diversity and inclusion, and leadership in the field.

Core Values

• Interaction/Integration: Facilitate the exchange of information and education among discovery and translational researchers, clinicians, early career investigators, societies and groups sharing the mission of SITC
• Innovation: Challenge the thinking, seek and advance the best research in the development of cancer immunotherapy
• Translation: Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
• Leadership: Define what is new and important and effectively communicate it to all relevant stakeholders
• Diversity & Inclusion: Elevate a diverse and inclusive community of researchers, practitioners, early career investigators and patients to advance care through immunotherapy

Goals

• Education and Scientific Exchange: Serve as the leading resource for information and education on cancer immunotherapy
• Professional Standards: Set industry standards for the field of cancer immunotherapy
• Global Access and Impact: Advance the science and application of, and equitable access to, cancer immunotherapy worldwide to eliminate disparities and improve outcomes
• Policy and Advocacy: Inform and influence the research, regulation, quality of patient care and equity of patient access impacted by public policy
• Science and Research: Challenge the thinking, seek and advance the best research to improve outcomes and develop tumor immunology and cancer immunotherapy
• Leadership Development: Cultivate the next generation of diverse leaders and innovators in tumor immunology and cancer immunotherapy
  

Year in Review